Schedule of Reportable Segments |
The following table presents information
about the Company’s reportable segments for the three months ended September 30, 2024 and 2023:
| |
Three Months Ended September 30, | |
| |
2024 | | |
2023 | |
| |
InMed | | |
BayMedica | | |
Total | | |
InMed | | |
BayMedica | | |
Total | |
| |
$ | | |
$ | | |
$ | | |
$ | | |
$ | | |
$ | |
| |
| | |
| | |
| | |
| | |
| | |
| |
Sales | |
| - | | |
| 1,264,638 | | |
| 1,264,638 | | |
| - | | |
| 901,862 | | |
| 901,862 | |
Cost of sales | |
| - | | |
| (771,225 | ) | |
| (771,225 | ) | |
| - | | |
| (880,620 | ) | |
| (880,620 | ) |
Research and development patents | |
| (762,874 | ) | |
| (8,306 | ) | |
| (771,180 | ) | |
| (1,271,439 | ) | |
| (20,654 | ) | |
| (1,292,093 | ) |
General and Administrative | |
| (1,238,181 | ) | |
| (183,745 | ) | |
| (1,421,926 | ) | |
| (1,063,660 | ) | |
| (235,071 | ) | |
| (1,298,731 | ) |
Amortization and depreciation | |
| (53,980 | ) | |
| (599 | ) | |
| (54,579 | ) | |
| (54,241 | ) | |
| (591 | ) | |
| (54,832 | ) |
Foreign exchange gain (loss) | |
| 19,310 | | |
| - | | |
| 19,310 | | |
| (48,457 | ) | |
| - | | |
| (48,457 | ) |
Interest and other income | |
| 57,094 | | |
| - | | |
| 57,094 | | |
| 136,043 | | |
| - | | |
| 136,043 | |
Net Income (Loss) | |
| (1,978,631 | ) | |
| 300,763 | | |
| (1,677,868 | ) | |
| (2,301,754 | ) | |
| (235,074 | ) | |
| (2,536,828 | ) |
Cash and Cash Equivalents | |
| 4,346,193 | | |
| 1,236,846 | | |
| 5,583,039 | | |
| 5,886,613 | | |
| 851,691 | | |
| 6,738,304 | |
|